A photo of Parinda Mehta.

Parinda A. Mehta, MD


  • Member, Division of Bone Marrow Transplantation and Immune Deficiency
  • Professor, UC Department of Pediatrics

About

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

Selected

Busulfan Pharmacokinetics and Precision Dosing: Are Patients with Fanconi Anemia Different?. Mehta, PA; Emoto, C; Fukuda, T; Seyboth, B; Teusink-Cross, A; Davies, SM; Wilhelm, J; Fuller, K; Vinks, AA; Boulad, F. Biology of Blood and Marrow Transplantation. 2019; 25:2416-2421.

Selected

Unique Challenges of Hematopoietic Cell Transplantation in Adolescent and Young Adults with Hematologic Malignancies. Mehta, PA; Rotz, SJ; Majhail, NS. Biology of Blood and Marrow Transplantation. 2018; 24:e11-e19.

Selected

Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. Dvorak, CC; Satwani, P; Stieglitz, E; Cairo, MS; Dang, H; Pei, Q; Gao, Y; Wall, D; Mazor, T; Olshen, AB; et al. Pediatric Blood and Cancer. 2018; 65.

Selected

Micafungin antifungal prophylaxis in children undergoing HSCT: can we give higher doses, less frequently? A pharmacokinetic study. Chandra, S; Fukuda, T; Mizuno, K; Davies, SM; Teusink-Cross, A; Tarin, R; Marsh, RA; Vinks, AA; Mehta, PA. Journal of Antimicrobial Chemotherapy. 2018; 73:1651-1658.

Quercetin ameliorates XIAP deficiency-associated hyperinflammation. Chiang, SC C; Owsley, E; Panchal, N; Chaturvedi, V; Terrell, CE; Jordan, MB; Mehta, PA; Davies, SM; Akeno, N; Booth, C; et al. Blood. 2022; 140:706-715.

Head and Neck Cancer Susceptibility and Metabolism in Fanconi Anemia. Chihanga, T; Vicente-Muñoz, S; Ruiz-Torres, S; Pal, B; Sertorio, M; Andreassen, PR; Khoury, R; Mehta, P; Davies, SM; Lane, AN; et al. Cancers. 2022; 14.

Influence of CYP2D6 metabolizer status on ondansetron efficacy in pediatric patients undergoing hematopoietic stem cell transplantation: A case series. Edwards, A; Teusink-Cross, A; Martin, LJ; Prows, CA; Mehta, PA; Ramsey, LB. Clinical and Translational Science. 2022; 15:610-618.

Ruxolitinib for the Treatment of Chronic GVHD and Overlap Syndrome in Children and Young Adults. Wang, YZ M; Teusink-Cross, A; Elborai, Y; Krupski, MC; Nelson, AS; Grimley, MS; Flannery, A; Mehta, PA; Bleesing, JJ; Chandra, S; et al. Transplantation. 2022; 106:412-419.

Test-dose pharmacokinetics guided melphalan dose adjustment in reduced intensity conditioning allogeneic transplant for non-malignant disorders. Chandra, S; Mizuno, K; Zhao, J; Davies, SM; Marsh, RA; Fukuda, T; Setchell, KD R; Vinks, AA; Mehta, PA. British Journal of Clinical Pharmacology. 2022; 88:115-127.

Model-informed precision dosing for alemtuzumab in paediatric and young adult patients undergoing allogeneic haematopoietic cell transplantation. Dong, M; Emoto, C; Fukuda, T; Arnold, DE; Mehta, PA; Marsh, RA; Vinks, AA. British Journal of Clinical Pharmacology. 2022; 88:248-259.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey